Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study

Thomas J A Lehman; Sharon J Schechter; Robert P Sundel; Sheila K Oliveira; Anna Huttenlocher; Karen B Onel

doi:10.1016/j.jpeds.2004.08.020

Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study

J Pediatr. 2004 Dec;145(6):856-7. doi: 10.1016/j.jpeds.2004.08.020.

Authors

Thomas J A Lehman¹, Sharon J Schechter, Robert P Sundel, Sheila K Oliveira, Anna Huttenlocher, Karen B Onel

Affiliation

¹ Division of Pediatric Rheumatology, Hospital for Special Surgery, and the Department of Pediatrics, Sanford Weill Medical College of Cornell University, New York, New York, USA.

PMID: 15580219
DOI: 10.1016/j.jpeds.2004.08.020

Abstract

Thirteen children with difficult systemic onset juvenile rheumatoid arthritis were treated with thalidomide. At 6 months, 11 of the 13 were able to reduce their use of prednisone ( P < .002), with a concurrent improvement in erythrocyte sedimentation rate ( P < .0001) and an increase in hemoglobin level ( P < 0.005). Juvenile rheumatoid arthritis improvement scores >/=50% were obtained by 10 of the 13 children.

Publication types

Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Arthritis, Juvenile / drug therapy*
Blood Sedimentation / drug effects
Child
Female
Humans
Immunosuppressive Agents / therapeutic use*
Male
Thalidomide / therapeutic use*
Treatment Outcome

Substances

Immunosuppressive Agents
Thalidomide